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 Abstract 
Dilated cardiomyopathy, DCM, affects both dogs and humans, and environmental 
factors, individual status and genetic causes are known or suspected. DCM is a heart 
disease where the cardiac muscle increases in size (hypertrophy), as the heart gets 
dilated and systolic (contractile) pressure decrease. The ineffective contraction is the 
fundamental defect in DCM. Inherited DCM in humans is a heterogeneous disease 
with many known causative genes. These known genes can be used as candidate 
genes for DCM in other species, for example the dog. The inherited variant of DCM 
in dog appears to be homogeneous within a breed and together with high linkage 
disequilibrium (LD), which means that large genomic regions are inherited together, 
dogs are preferable to use in genetic studies. Markers in the genome are compared 
between individuals to see which regions are shared between individuals.   
The overall aim with the DCM project is to determine the genetic association with 
DCM in Newfoundland dogs. The study reported here is a part of the DCM project 
and includes an evaluation of genomic DNA from paraffin-embedded tissue for use in 
genetic studies and a candidate gene approach where association between desmin and 
DCM was evaluated.  
 Genomic DNA extracted from paraffin-embedded tissue was tested in PCR with 
and without additional purification steps. All tests indicated that the quality varied 
between different paraffin blocks and that most samples contained highly degraded 
genomic DNA. The genomic DNA could still be used to amplify fragments including 
microsatellites around desmin from several individuals. Only with two of the 
microsatellites, fragments were amplified in sufficient number of individuals and the 
desmin haplotype therefore only consists of two markers separated by 15.4 kb. One of 
these markers was in addition uninformative (95 % of the tested alleles had the same 
length). This means that the results should be considered with caution, but they 
indicated no association between a desmin haplotype and the disease.  
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1. Abbreviations 
bp   base pair/s 
DCM  dilated cardiomyopathy 
dNTP deoxyribonucleoside triphosphate 
gDNA genomic DNA (deoxyribonucleic acid) 
kb   kilobase/s 
LD  linkage disequilibrium 
PCR  Polymerase chain reaction 
SNP  single nucleotide polymorphism 
SLU  Sveriges lantbruksuniversitet (Swedish University of Agricultural Sciences) 
 
2. Introduction 
The overall purpose of the DCM project is to find genetic association with dilated 
cardiomyopathy, DCM, in Newfoundland dogs. This knowledge has importance to 
breed healthier dogs by using dogs without mutated genes in breeding. It can also 
have importance when the disease in human is studied. Although much is known 
about DCM in human, this knowledge can have a comparative value.  
 The Newfoundland breed was chosen because many blocks of paraffin-embedded 
cardiac tissue are present, which might be used as DNA source for genetic studies. 
Newfoundland dogs are also an over-represented breed to develop DCM compared to 
many other breeds (Tidholm & Jönsson 1997). 
 This study was a part of the overall DCM project and in this study the purpose was 
to evaluate if the gene encoding the muscle specific intermediate filament desmin 
contains a causative mutation for DCM in Newfoundland dogs. For this study 
genomic DNA, gDNA, from paraffin-embedded tissue was used and also evaluated as 
possible gDNA source for other studies.  
  
2.1 Design of the project 
First a method to extract gDNA from paraffin-embedded tissue was chosen by 
evaluating two methods for paraffin purification and two methods for DNA 
extraction. The quality of the extracted gDNA was evaluated and other purification 
steps were tested in effort to improve the quality. After evaluation of the extracted 
gDNA it was used as samples in the candidate gene approach to evaluate if the desmin 
gene is associated with DCM in Newfoundland dogs. Microsatellites around the 
desmin gene were used as markers and their lengths were gathered to haplotypes. 
Their possible association with DCM was then evaluated, by comparing haplotypes 
between individuals (cases and controls).  
 
 2.2 DCM 
Literally the term cardiomyopathy means heart muscle disease and it is used to 
describe heart diseases resulting from a primary abnormality in the myocardium. 
Cardiomyopathies are traditionally divided in three major clinicopathologic groups; 
dilated, hypertrophic and restrictive (Kumar et al. 2003). Hypertrophic and restrictive 
will not be explained further in this study. Dilated cardiomyopathy occurs in a variety 
of species, notably dogs, cats and humans (Tidholm & Jönsson 1996) and it is 
characterized by progressive cardiac hypertrophy, which mean increased size of the 
heart (without cell division), dilation and contractile (systolic) dysfunction. The 
ineffective contraction is the fundamental defect in DCM.  
 The causes of DCM are not always known but can be a result of viral infections or 
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toxic components or be inherited (Kumar et al. 2003). DCM in dogs is suspected to be 
inherited because of its prevalence in certain breeds and in specific families. Also 
several other causes have been suggested in dog, including nutritional deficiencies, 
metabolic disorders, immunologic abnormalities, infectious diseases and decreased 
contractile function of the left ventricle (myocardial hypokinesis) induced by drugs, 
toxins or abnormally rapid heart beats (tachycardia) (Tidholm & Jönsson 2005).  
 In a swedish study by Tidholm and Jönsson (1997) DCM were found in 38 dog 
breeds, in an age range of 3.5 months to 13 years. 92% of the animals weighed over 
15 kg (and 15% over 50 kg), resulting in predominance for DCM in large- and 
medium-sized breeds weighing more than 15 kg (but less than 50 kg). The study 
included 189 dogs diagnosed with congestive heart failure caused by DCM. The 
breeds Airedale terrier, Boxer, Doberman, Newfoundland, Standard poodles, St. 
Bernard and English cocker spaniel were significantly over-represented (Tidholm & 
Jönsson 1997). The clinical signs in dogs with DCM are cough, depression, exercise 
intolerance, inappetence, breathing difficulties (dyspnea), weight loss, abdominal 
distension, panting, syncope, excessive thirst (polydipsia), weak pulse, systolic 
murmur and excess fluid in the peritoneal cavity (ascites) (Tidholm & Jönsson 1995 
& 1997). 
 Dogs that are clinically diagnosed with DCM reveal two distinct histological forms 
of DCM. Cardiomyopathy of Boxers and Doberman Pinschers are called “fatty 
infiltration-degenerative” type and in many giant, large- and medium-sized breeds 
DCM can be classified as “attenuated wavy fiber” type. Attenuated wavy fibers are 
myofibers that are thinner than normal and have wavy appearance. The fibers are 
separated by a clear space with oedematous fluid and in some cases there is also a 
diffuse infiltration of subendocardial fibrosis (Tidholm & Jönsson 2005). In a study, 
64 of 65 (98%) dogs with confirmed DCM were positive for attenuated wavy fibers. 
In 147 dogs with other heart disease than DCM only one had trace of attenuated 
fibers, although not in sufficient numbers to be classified as a positive finding. With 
these results Tidholm and others (1998) suggested that a histological examination for 
attenuated wavy fibers might be a useful postmortem test for DCM in dogs and it is 
said to have a high specificity and sensitivity for DCM. Histopathological changes 
have also been reported as being characteristic for DCM in humans (Davies 1984). 
 Inherited DCM in humans is a genetically heterogeneous disease, meaning that 
many genes are linked to the disorder, possibly giving rise to different phenotypes 
(Fatkin & Graham 2002). When comparing individuals affected by DCM within dog 
breeds it appears to be relatively homogenous in separate breeds. This makes the dogs 
a good model to study the genetic background of spontaneously occurring DCM and 
possibly associate it to DCM in humans (Stabej et al. 2006). Lindbladh-Toh and 
others (2005) studied human and dog othologous sequences and suggested that the 
there is a common set of functional elements across the species. Dogs within each 
breed also have extensive linkage disequilibrium, LD, which means that large 
fragments in the genome are inherited as blocks. They also have relatively low 
diversity of haplotypes, where alleles in 80 % of a chromosome only have two to four 
alleles (Sutter et al. 2004). This means that fewer markers are needed when 
performing a whole-genome association study compared to humans (Lindbladh-Toh 
et al. 2005). In addition only population-based samples are required in difference to 
linkage mapping, where many generations of families are needed (Sutter et al. 2004).  
 
 
 
 - 5 -
2.3 Newfoundland breed 
The Newfoundland breed has an increased incidence for DCM (Tidholm & Jönsson 
1997) and shows attenuated wavy fibers (Tidholm et al. 1998). Even seven of 15 
examined Newfoundland dogs without any abnormalities in echocardiographical 
examination or clinical signs for heart disease have been reported to be positive for 
attenuated wavy fibers. None of 32 other breeds without myocardial abnormalities 
showed attenuated wavy fibers (Tidholm et al. 2000). Since attenuated fibers have 
been shown to have high specificity and sensitivity for DCM (Tidholm et al. 1998) 
these results are, by Tidholm and others (2000), indicating that development of 
attenuated wavy fibers may represent an early stage of DCM. They also mean that 
development of attenuated wavy fibers is most probably not a response to chamber 
dilation and stretching of the myocytes, as suggested by Scheinin and others (1992). A 
biopsy from such individuals should make it possible to detect future development of 
DCM in a clinical healthy dog, but unfortunately biopsies for this kind of examination 
can not be taken in a living dog (Tidholm et al. 2000). Instead, it is of great interest to 
find a tool for predicting future cases using other methods; whole-genome association 
mapping is one suggestion.  
 The mode of inheritance indicates how many samples are required in a whole-
genome association scan. The mode of inheritance of DCM seems to vary between 
breeds and has not been clearly defined in most breeds (Alroy et al. 2000) but an 
autosomal dominant mode of inheritance has been suggested in the Newfoundland 
breed (Göran Andersson, unpublished observation). If this is correct about 50 cases 
and 50 controls are needed to obtain statistically significant results from an 
association mapping, according to Karlsson and others (2007, in preparation). Whole 
genome association scan is expensive and sample collection is time consuming; 
however, it is possible to evaluate individual genes, prior performing a whole-genome 
association scan, utilizing a so-called candidate gene approach. In the current study 
the desmin gene has been chosen as a candidate.  
 
2.4 Candidate gene  
To find a candidate gene for DCM, three main molecular pathways involved in DCM 
listed by Stabej and others (2006) can be studied. The first is disturbed integrity of the 
cytoskeleton, second is disturbed Calcium kinetics and sensitivity and the third is 
impaired intracellular signalling mechanism. One way, as in this study, is to choose 
one that is known to cause DCM in humans. The one chosen for this study has also 
been excluded in Doberman (Stabej et al. 2004). A common feature of DCM in 
humans is disruption of cytoskeletal integrity (Franz et al. 2001) and one example of a 
cause of DCM is a missense mutation in the gene encoding the intermediate filament 
desmin (Li et al. 1999). Newfoundland dogs show attenuated wavy fibers (Tidholm et 
al. 1998), which might be due to a structural mutation. Therefore the gene encoding 
the structural protein desmin was chosen as candidate for DCM in Newfoundland 
dogs.  
 
  2.4.1 Desmin 
Desmin expression is restricted mostly to muscle tissue and is concentrated at Z discs 
in smooth, skeletal and cardiac muscle cells. Desmin is an intermediate filament that 
link individual myofibrils, which build up the muscle cell, (Lazarides 1982) and form 
a three-dimensional scaffold throughout the extrasarcomeric cytoskeleton. The 
extrasarcomeric cytoskeleton is a complex network of proteins linking the sarcomere 
(the contractile unit that builds up the myofibrils) with the sarcolemma (which 
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surrounds the cell) and the extracellular matrix (in the space between cells). This 
network provides structural support for subcellular structures and transmits 
mechanical and chemical signals within and between cells (Franz et al. 2001). During 
assembly of myofibrils in biogenesis, desmin may play an important role in the 
generation of the striated appearance of a muscle (Lazarides 1982). A desmin defect 
might then be a possible reason for the wavy fiber appearance observed in diseased 
dogs.  
The effect on myocardial mass, myocyte shape and cardiac systolic and diastolic 
function in absence of desmin has been studied in knock-out mice lacking desmin. 
This study, reported by Milner and others (1999), was performed in order to find the 
involvement of desmin in cardiomyopathies and in normal cardiac function. The mice 
lacking desmin showed development of cardiac hypertrophy with ventricular dilation, 
compromised systolic function and heart failure later in life. Their hearts were 
frequently enlarged when compared to hearts of normal mice and both right and left 
ventricular chambers were dilated. Histological and electron microscopic analysis in 
both heart and skeletal muscle tissues revealed severe disruption of muscle 
architecture and degeneration (Milner et al. 1996). Several reported cardiomyopathies 
have showed granular and filamentous aggregates of desmin (Goebel 1995), but there 
are no cases where desmin is completely absent (Milner et al. 1999). This might still 
not exclude that non-functional desmin can cause the disease. Milner and others 
(1999) report a similar theory while they argue that the phenotype of desmin null mice 
support the notion that the observed abnormalities in desmin distribution might have a 
causal effect.  
 Desmin has been evaluated as a causing gene in Doberman, and were concluded to 
not play a role in Doberman DCM (Stabej et al. 2004). This does not exclude desmin 
as a candidate for being the causative gene in Newfoundland since the two breeds do 
not even show the same type of DCM according to histopathological findings, where 
Doberman do not show wavy fibers (Tidholm & Jönsson 2005).  
 
2.5 Tools in molecular genetics 
  2.5.1 Genetic polymorphism  
All genomes consist of genetic polymorphism, which are sequences that are found in 
two or more variants (alleles) within a population. If the variants persist in the 
population with allele frequencies above 1 % for the rarest allele it is called a genetic 
polymorphism. Single nucleotide polymorphisms (SNPs) and microsatellites are 
examples of such genetic polymorphism. These can be used as genetic markers to 
create a haplotype, which can be used to determine association between a haplotype 
and a phenotype. A haplotype covers a genomic region that is not separated by 
recombination, which means that markers segregate together, in so-called linkage 
disequilibrium (LD). LD can for example arise from non-random mating (Gibson & 
Muse 2004). Since dogs have a history of inbreeding and restricted amount of 
founders for one breed, they have a high degree of LD. This result in longer 
haplotypes compared to humans, because the markers are linked and inherited 
together in a higher frequency than expected (Sutter et al. 2004).  
  
  2.5.2 Microsatellites 
Microsatellites are tandemly repeated DNA and consists of a 1-, 2-, 3-, 4- or 5- base 
pair repeated unit (Brown 2002, Page  & Holmes 1998). Microsatellites can, as 
mentioned, be polymorphic, where the number of repeated units differs between 
alleles in individuals of a species. The different lengths can create an individual 
 - 7 -
genetic profile, which can be used in forensic science or to establish relationship. 
Microsatellites are popular as markers because of this polymorphism and because they 
are randomly spread over the genome. They are also relatively short which make them 
easy (fast and accurate) to amplify in PCR (Brown 2002). Microsatellites are thought 
to be produced by mutation, unequal crossing-over and DNA slippage. DNA slippage 
occurs when DNA strands mispair during replication and recombination. One DNA 
strand creates a loop and the DNA repair mechanism will either remove the loop 
(decrease in size) or put in new nucleotides in the created gap (increase in size) (Page 
& Holmes 1998). This can also happen in PCR and should be considered when 
analysing the measured lengths of microsatellites amplified in PCR.  
 In this study microsatellites were used to define haplotypes found in the study 
population. In a microsatellite analysis microsatellites around a gene are chosen and 
the alleles of each selected microsatellite are defined in each individual. This data are 
used to calculate the observed and possible haplotypes in the individuals. The 
haplotypes are compared between cases and controls to see if a haplotype is 
associated with the phenotype. If there is no association between any of the observed 
haplotypes and the phenotype the number of cases are expected to be the same as the 
number of controls. The observed number is compared to the expected number and a 
χ2 value can be calculated.  
 
3. Material & method 
 3.1 Samples 
Cardiac tissue, from deceased Newfoundland dogs with or without DCM, has been 
collected by veterinarian Anna Tidholm (Albano Animal hospital, Stockholm). The 
tissues were prepared with 4% buffered formalin and washed two times with 70% 
ethanol, one time with 80% ethanol, two times with 95% ethanol and one time with 
99,5% ethanol followed by two times preparation with 100% xylene and finally 
embedding in paraffin for histology (Professor Lennart Jönsson, Department of 
Pathology, SLU, Uppsala, personal notification). 
After histological findings the blocks were given to the Department of Animal 
Breeding and Genetics to be examined for use in genetic studies. 72 paraffin blocks 
were used (43 cases and 29 controls) and all these samples are listed in appendix 1. 
From a few individuals there are blood samples too, but they were not used in this 
study. They can be used to confirm these results and/or be saved for future studies, for 
example whole genome association mapping.  
 
3.2 Evaluation of DNA-preparation method  
and gDNA from paraffin-embedded tissue  
  3.2.1 DNA extraction  
Two methods to purify the tissue samples from paraffin were tested. In the first 
protocol; octane/methanol-protocol, (appendix 2a), the paraffin was detached from the 
tissue with n-octane and the tissue was protected with a small volume of 100% 
methanol when the n-octane layer with paraffin was removed. The methanol was then 
removed from the tissue before DNA extraction. In the other protocol; xylene-
protocol, (appendix 2b), xylene was used to remove paraffin. After vortex and 
centrifugation xylene that had bound the paraffin was removed. The tissue was 
washed with absolute ethanol before DNA extraction. These paraffin purification 
protocols were tested before two DNA extraction methods; extraction with a standard 
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(salt) protocol (appendix 3) and E.Z.N.A. tissue DNA kit. All combinations were 
evaluated.  
 After evaluation octane/methanol protocol and standard (salt) protocol were used 
to purify the samples from paraffin and extract gDNA from the paraffin blocks listed 
in appendix 1. One additional step was made from the tested protocol. After 
precipitation the pellets were washed with 70% ethanol to remove any trace of NaCl, 
which was bound by the 30% water in the solution. All samples were tested to 
amplify a 600 bp fragment in PCR to see which have potential to be used in future 
studies. The samples were also used in a candidate gene approach. Both tests are 
explained later in this report.  
 
  3.2.2 Extraction evaluation 
To evaluate which extraction method to use, samples from the same paraffin block 
(individual NF115) were used to make the comparison more accurate. These samples 
are called the evaluation samples. The block from NF115 was chosen only because 
more blocks were available for that individual. Both the evaluation samples and some 
other samples, included in this evaluation, were weighed before preparation to 
calculate the yield of ng DNA per mg tissue. The DNA concentration and purity (OD 
260 nm/280 nm ratio) were measured in NanoDrop ND1000 Spectrophotometer. 
According to the NanoDrop manual the OD 260/280 ratio for gDNA are acceptable 
between 1.8 and 2.0.  
  
3.2.2.1 Agarose gel electrophoresis 
The prepared samples were run on a 1% agarose gel (SeaKem®GTG®Agarose ≥ 1kb) 
to see if there was any gDNA in the samples. This method was also used to see if 
tested PCRs were able to amplify a fragment of expected size.    
 
3.2.2.2 PCR 
Polymerase chain reaction, PCR, was used to evaluate the quality of the gDNA after 
preparation. In PCR the DNA strands are separated, specific primers anneal and new 
nucleotides build up a new strand (a copy) at different temperatures in several cycles.  
The nucleotide binding is supported by a polymerase and a PCR buffer and MgCl2 are 
present to create optimal conditions. The primers anneal to specific locations in the 
DNA and the product will therefore have different size according to which primer pair 
is used.  
Different PCR protocols were performed and primer pair for 250 bp fragments, 
600 bp fragments and 1.500 bp (1.5 kb) were tested, (see appendix 4 for 250 bp- and 
600 bp- PCR).  
PCR products of 250 bp were gel purified (after separation with agarose gel 
electrophoresis) using E.Z.N.A. Gel Extraction Kit. After gel purification the PCR 
products were sequenced in MegaBACE 1000 to evaluate the quality of the gDNA. 
The analysis was made in the computer software CodonCode Alignment (v.1.6.2).  
 
3.2.3 Evaluation of gDNA from paraffin-embedded tissue 
To evaluate the quality of gDNA from paraffin-embedded tissue both evaluation 
samples and other samples were used. This evaluation was performed in collaboration 
with research assistant Katarina Stenshamn (Small Animal Clinical Sciences, SLU, 
Uppsala) who extracted gDNA from paraffin-embedded renal tissue from boxers. The 
same preparations were used for her samples and all samples were therefore 
considered to be comparable.  
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The evaluation consisted of testing different PCR with and without additional 
purification steps, which are described later.  
 
   3.2.3.1 PCR and primer design 
The same PCR protocol for a 600 bp-fragments as tested with the evaluation sample 
was tested with some additional samples (see appendix 4 for PCR protocol). To see if 
a slightly longer fragment could be amplified a fragment of around 800 bp was 
chosen. The longer fragments that can be amplified in PCR, the higher is the 
possibility to use the sample in a genome scan.  
 Primers to amplify a fragment of around 800 bp including regulatory sequence 
upstream the desmin gene were designed (see table 1). The fragment should start 
approximately 50 bp downstream the Cap-site (transcription start) and then follow 
upstream to get a fragment size of around 800 bp. A sequence was retrieved from 
Ensembl Dog (release 40, Aug 2006) containing exon 1 and 1500 bp upstream ATG. 
The Cap-site was found by comparing the dog and human sequences with known 
position of the TATA-box and Cap-site (Zhenlin Li et al. 1989). The retrieved dog 
sequence with the target (50 bp downstream Cap-site and 700 bp upstream) marked 
with brackets was pasted in the program Primer3 (Primer3’s homepage), which 
suggested some primer pairs. One primer pair (one forward and one reverse primer) 
were chosen and ordered from TAG Copenhagen A/S online (Tag Copenhagen’s 
homepage). The regulatory sequence was chosen because of possible additional use in 
future regulatory studies.   
 
Table 1. Primer design for an 850 bp fragment of regulatory sequence of desmin. 
Name: Sequence: Tm  
(primer3 / TAGC) 
Length: 
regDesF TGTCCCAGGACTGCTCTCTG 61.59 / 61.4 20 bases 
regDesR TAGGCCTGGCTCATGCTG 61.10 / 58.2 18 bases 
 
Although both primers only had complete match to the wanted positions in the dog 
genome, according to the BLAT function at UCSC Genome Browser (Dog assembly 
May 2005) and Ensembl Dog BLAST (release 41, Oct 2006), this primer pair gave 
two PCR products of unexpected size instead of one 850 bp fragment in control 
samples of boxer gDNA and gDNA from a cross breed. The PCR program was 
modified to increase the stringency and betaine was added in the PCR-mix to make 
the template more available but the two PCR products remained unchanged. 
To be sure to get at least one functional primer pair, two new primer pairs were 
designed and ordered. The sequence of the desmin gene with flanking regions was 
retrieved from Ensembl Dog (release 41, Oct 2006). It was not possible to design 
primers for a new fragment of a correct size in the promoter region close to desmin. If 
the target was moved more inside the gene the forward primer was placed in either a 
region of around 350 bp with many repetitions or in a region of around 350 bp that 
also could be found on another chromosome. If the target was moved more upstream 
the gene the primer design programme, Primer3 (Primer3’s homepage), could not find 
any primers. Instead two fragments inside the gene were used to find possible primers. 
The first primer pair designed covered exon 4, 5 and 6 and should according to the 
Ensembl sequence give a fragment of 846 bp. The second primer pair should amplify 
a fragment of 826 bp covering exon 7. See table 2 for primer sequences and other 
information. The program Netprimer (Netprimer’s homepage) was used to evaluate 
the structure of the primers and the primer sequences were also compared to the dog 
genome with the BLAT search in UCSC Genome Browser (Dog assembly, May 
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2005) to see that they only had perfect matches to the wanted positions. The chosen 
primers were ordered from TAG Copenhagen A/S online (Tag Copenhagen’s 
homepage). See appendix 4 for PCR protocol.  
 
Table 2. Primer design for fragments over 800 bp inside the desmin gene. 
Name: Sequence: Tm  
(primer3 / TAGC) 
Length: 
Des_ex456F TTACCCCTTTGACCCCTTGT 60.58 / 57.3 20 bases 
Des_ex456R TGAGAGCCAAGGTCATAGCA 59.55 / 57.3 20 bases 
Des_ex7F ACCTGGGTGTCCCTCTCCT 60.93 / 61.0 19 bases 
Des_ex7R CAAGATACATAACGTCTCCATCG 58.66 / 58.9 23 bases 
 
3.2.3.2 Purification of the gDNA 
DNA fragments of low molecular weight were suggested to disturb PCR and spin 
columns were used to remove different sizes of fragments before PCR. A spin 
column, ”BD Chroma SpinTM-400”, that according to the BD CHROMA SPINTM 
Columns User Manual removes fragments smaller than 170 bp were tested and some 
samples were also purified with phenol/chloroform (appendix 5) before, after or 
without spin column. The different combinations were tested in both 600 bp- and 1.5 
kb- PCR.  
Spin columns that removes smaller fragments were also tested. “BD Chroma 
SpinTM-10”, which removes most fragments below 4 bp (i.e. NTPs, dNTPs) and NaCl, 
and “BD Chroma SpinTM-100”, which remove most fragments below 50 bp (BD 
CHROMA SPINTM Columns User Manual), were tested before PCR to amplify an 
850 bp fragment. Samples run through a dry “BD Chroma SpinTM-10”, were tested in 
a 600 bp PCR. Before adding the sample to the spin column it should spin down. 
Unfortunately, this time the centrifuge was wrongly programmed and the spin 
columns went too dry. A large amount of the DNA from these samples remained in 
the column and the results from this test are therefore not completely reliable.  
   
3.2.3.3 Optimizing PCR for gDNA from paraffin- embedded tissue 
To improve the results, optimization of the PCR conditions were tried. To decrease 
the specificity and perhaps increase the yield the MgCl2 and primer concentration 
were altered and tested in 600 bp PCR. MgCl2 concentration of 2.0 mM, 2.5 mM and 
3.0mM were tested in combination with a primer concentration of 0.2 µM and 0.4 
µM. The best combination of primer- and MgCl2- concentration was used in the 850 
bp PCR with spin column (BD Chroma SpinTM-10 and -100) samples.  
After searching for ideas to optimize PCR with degraded and perhaps 
contaminated DNA, such as ancient DNA, a test with different dilutions of DNA 
template were performed in 600 bp PCR. The tested dilutions were 100 ng/reaction, 
50 ng/reaction, 25 ng/reaction, 10 ng/reaction and 2 ng/reaction, in a 20 µl reaction. 
Diluting DNA template will also dilute disturbing contaminations and less 
contamination will be present in the PCR. Amplifying will anyhow be possible, 
because of the high sensitivity of PCR, which in theory only require a single DNA 
molecule as template.  
  
 3.3 Candidate gene approach 
To evaluate whether desmin is a DCM causing gene in Newfoundlands, three genetic 
markers that cover the gene were used to define the haplotypes present in different 
individuals, cases and controls. gDNA from the paraffin blocks listed in appendix 1 
were used.  
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  3.3.1 Bioinformatics 
The sequence of the gene and 10 kb upstream and downstream were first found in the 
first version of the dog genome (CanFam1), where the gene was searchable (in 
Ensembl release 40, Aug 2006). In the unfinished, latest version, of the dog genome 
sequence (CanFam2) in Ensembl (pre-dog) (Ensembl v.38) the sequence between the 
same positions was found, but did not match the first. The start of the first sequence 
(that was retrieved with the gene name in CanFam1) was found manually in the 
CanFam2-sequence. The start position and the size of the wanted fragment were 
calculated with the known positions from CanFam1. The new sequence (in CanFam2) 
started at 28.923.171 and ended at 28.949.704. The desmin gene is then found at 
chromosome 37 between 28.933.171 and 28.939.704 in the latest version of the Dog 
genome (CanFam2) with a size of 6.5 kb. These positions were needed to find the 
microsatellites found by UCSC Genome Browser (Dog May 2005 (CanFam2) 
assembly). In the upgraded Ensembl Dog (release 42, Dec 2006) the location of the 
desmin gene in CanFam2 is between 28.933.165 and 28.939.896 at chromosome 37.  
 
3.3.1.1 Microsatellites around desmin 
UCSC Genome Browser (Dog May 2005 (CanFam2) assembly) was used to find 
repeats and possible microsatellites in the sequence. Two from UCSC Genome 
Browser (the first and third) and one found manually (the second) were chosen as 
markers for the desmin gene. The first microsatellite is a CT-repeat (~20 repetitions) 
located around 5.1 kb upstream desmin, the second is a GT-repeat (~12 repetitions) 
located around 2.4 kb upstream desmin and the third is an ATTTT-repeat (~8 
repetitions) located around 6.5 kb downstream desmin. In total, these microsatellites 
will define a haplotype with the size of 18.1 kb around the desmin gene. Table 3 
present a microsatellite summary and figure 1 gives an overview of the region covered 
by the microsatellites and the region to be included in the desmin haplotype. 
 
Table 3. Microsatellite summary 
Name Repeat No of 
repeats 
Distance 
in bp 
from 
desmin 
PCR 
product 
(bp) 
Forward primer  
(5’-3’) 
Reverse primer  
(5’-3’) 
Des1 CT ~20 5,091 (5’) 295 TGCAAGACGCTGTACCACAT GTTGGAAATGGGAAGGTTCA 
Des2 GT ~12 2,385 (5’) 227 GGCTCCAGTTTACGAATTGC GGCAAGCTTTCTGTCCTGTC 
Des3 ATTTT ~8 6,485 (3’) 104 TTAGGGCATGGAACTGCTCT ATACTGGGCATGGAACAACC 
Figure 1. An overview of the desmin gene located at chromosome 37 between 
28.933.171 and 28.939.704 (in CanFam2) with a size of 6.5 kb. The three 
microsatellites are marked and covers a region of 18.1 kb. (UCSC Genome Browser -
Dog May 2005 (CanFam2) assembly) 
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  3.3.2 PCR and primer design 
Primer3 (Primer3’s homepage) was used to design the primers to amplify fragments 
including the microsatellites, see table 3. The program Netprimer (Netprimer’s 
homepage) was used to evaluate the structure of the primers and the primer sequences 
were also compared to the dog genome with the BLAT search in UCSC Genome 
Browser (Dog assembly, May 2005) to see that they only had perfectly matches to the 
wanted positions. A M13 (-21) tail, (5´-CACGACGTTGTAAAACGAC-3´), was 
added to the 5’-end of all forward primers and then the primers were ordered from 
TAG Copenhagen A/S online (Tag Copenhagen’s homepage).  
 The M13 tail is needed for labelling the PCR products for detection by laser in 
MegaBACE when genotyping. Instead of labelling each primer with separate dyes a 
universal fluorescent-labelled M13 (-21) primer can be used. During the first cycles in 
PCR the forward primer with the M13 (-21) tail and the reverse primer anneal to the 
DNA template to amplify the wanted region. The M13 (-21) tail gets incorporated in 
the PCR product and becomes target for the labelled universal M13 (-21) primers in 
following cycles. In this way the labelling gets incorporated in the PCR product 
(Schuelke 2000).  
 Different PCR mixes and programs were tested and the best one was used to 
amplify the microsatellite fragments (see appendix 4). The fluorescent dyes in the 
labelled M13 (-21) primers used were TET (6-carboxy-fluorescine) for Des 1 and Des 
3, and FAM (tetrachloro-6-carboxy-fluorescine) for Des 2.  
 All samples were tested on 1% agarose gel (Invitrogen AGAROSE 
ELECTROPHORESIS GRADE) to see if there were any PCR products. Even 
samples that showed weak bands were tested in MegaBACE for genotyping.  
 
  3.3.3 MegaBACE, Genotyping 
A buffer plate containing 190 µl 1 x MegaBACETM LPA buffer in each well was 
prepared before each MegaBACE run. The PCR products were first diluted. Since 
Des 2 and Des 3 had different labelling they were run together for one individual in 
the same well (multiplexing). 1.5 µl of each PCR product and 3 µl milliQ water were 
mixed. Des 1 were run in separate wells and where diluted with 1.5 µl PCR product 
and 4.5 µl milliQ water. Some samples, which showed low intensity when analysing 
the MegaBACE result, were less diluted (3 µl PCR product in a total volume of 6µl) 
before a second try in MegaBACE. The diluted PCR products were put on a 
MegaBACE plate containing 5 µl diluted (1:20) size standard (ET 400-R) in each 
well. Before MegaBACE run the buffer plate and MegaBACE plate were centrifuged 
at 2.000 x g for 2 minutes. Six matrix tubes were also centrifuged at 3.000 x g for 3 
minutes. When starting the MegaBACE run the instructions in the machine were 
followed.  
The lengths of the PCR products (the fragments including the microsatellites) were 
detected by laser in the MegaBACE and by comparing the lengths with the size 
standard each microsatellite allele got a relative length. The raw data from the 
MegaBACE run were analysed with the MegaBACETM Genetic Profiler version 2.2 
(Amersham Biosciences). In this analysis peaks with highest intensity are possibly the 
true alleles. Other peaks around, so-called stutter peaks, are probably due to DNA 
slippage in PCR. Assembling all alleles for one individual give the haplotype for this 
individual. The single alleles and the haplotypes can be compared to the ones of other 
individuals and by statistical calculations a certain allele or haplotype can be 
associated (linked) or not to a certain disease, in this case DCM. The calculations for 
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analysis of genetic linkage were performed with the program CONTIG version 2.71 
(Utility programs for analysis of genetic linkage, copyright 1988, J. Ott).  
 
4. Results 
 4.1 Evaluation of DNA-preparation method 
The results for the evaluation samples (NF115) are listed in table 4. 
 
Table 4. Results of evaluation samples.  
New ID DNA-prep. Paraffin DNA  DNA 260/ Gel PCR PCR PCR  
    purifi- conc.  amount 280 >1kb? 250bp? 600bp? 1.5kb? 
    cation (ng/uL) (ng)   (fig.3)       
Octane/ 
S.oct.1 Salt prep. 
methanol 
357,3 17865 1,78 - yes yes no 
Octane/ 
S.oct.2 Salt prep. 
methanol 
216,8 10840 1,72 yes - - - 
S.xyl.1 Salt prep. Xylene 287,0 14350 1,81 yes yes yes no 
S.xyl.2 Salt prep. Xylene 497,8 24890 1,83 - - - - 
EZ.oct.wat.1 EZNA:1  
(water elution) Octane/ 94,5 9454 1,93 yes yes yes no 
EZ.oct.eb.1 EZNA:1 (2:nd 
elution with EB) methanol 77,1 7710 1,99 yes yes yes no 
EZ.oct.wat.2 EZNA:2  
(water elution) Octane/ 50,9 5086 1,95 - - - - 
EZ.oct.eb.2 EZNA:2  (2:nd 
elution with EB) methanol 35,7 3567 2,05 - - - - 
EZ.xyl.wat.1 EZNA:3  
(water elution) 58,7 5873 1,86 - yes 
yes 
(weak) no 
EZ.xyl.eb.1 EZNA:3  (2:nd 
elution with EB) 
Xylene 
42,4 4240 1,90 yes yes no no 
EZ.xyl.wat.2 EZNA:4 (water 
elution) 91,1 9109 2,01 yes - - - 
EZ.xyl.eb.2 EZNA:4 (2:nd 
elution with EB) 
Xylene 
29,7 2970 2,00 - - - - 
“EB” stands for Elution Buffer and “-“ means that the sample has not been tested. 
 
The 250 bp fragments amplified from the evaluation samples that were purified and 
sequenced in MegaBACE showed good quality. The evaluation samples were also run 
directly in agarose gel electrophoresis, which showed that the samples contained 
gDNA of both low- and high molecular weight, see figure 2. 
 
 
Figure 2. Gel picture of extracted gDNA from 
paraffin-embedded tissue. 
 
Each well were loaded with 20µl sample of 
following concentrations;  1) 95 ng/µl 
                            2) 90 ng/µl 
            3) 75 ng/µl 
            4) 40 ng/µl 
            5) 350 ng/µl 
            6) 300 ng/µl 
 
 
 
 
 
1kb
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Some samples, both evaluation samples and others, were weighed before purification 
and extraction. After concentration measurement with NanoDrop the yield of ng 
gDNA per mg tissue was calculated. Measurements for the yield calculations are 
listed in appendix 6. To visualise a possible correlation between the amount of tissue 
and the amount of extracted gDNA those values were plotted in a diagram, see figure 
3. To correlated the two lines should follow each other, but this shows no correlation. 
A small tissue part sometimes gives more DNA than a bigger tissue part, for example 
“S.oct.1” compared to “EZ.xyl.1”. This means that the yield is not due to how much 
tissue is prepared, but instead which tissue part is used. Therefore, the yield can not 
tell if one method is better.  
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Figure 3. Tissue weight and amount of extracted DNA plotted to visualise a possible 
association.  
 
In total, neither octane/methanol-protocol nor xylene-protocol gave better result than 
the other. The octane/methanol protocol was a bit easier and faster and was therefore 
used for paraffin purification of the original samples. There were no notable variation 
between the preparation protocols neither, therefore, by economical reasons; the 
standard (salt) protocol was chosen. 
 
 4.2 Evaluation of gDNA from paraffin-embedded tissue 
Many combinations of purification and PCR were tested. Samples purified with a BD 
Chroma SpinTM-400 could not amplify a 1.5 kb fragment. Not even when the samples 
were purified with phenol/chloroform before or after they could amplify a 1.5 kb 
fragment. Other results are presented in table 5.   
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Table 5.  Result of different purification steps before PCR.  
ID Purification 850bp PCR 600bp PCR 
NF113 Chroma Spin -400 Phenol/chloroform - no 
NF113 Phenol/chloroform   - no 
NF113 Phenol/chloroform Chroma Spin -400 - no 
105b (KS) Chroma Spin -400 Phenol/chloroform - no 
105b (KS) Phenol/chloroform   - no 
105b (KS) Phenol/chloroform Chroma Spin -400 - no 
Control DNA   - yes 
Control DNA Phenol/chloroform   - yes 
320b (KS)   - no 
320b (KS) Phenol/chloroform   -  no 
NF118   - yes 
NF118 Phenol/chloroform   - yes 
EZ.xyl.wat.1   - yes 
EZ.xyl.wat.1 Phenol/chloroform   - yes 
S.oct.1     -  yes 
S.oct.1 Chroma Spin -10 (dry) no yes 
320 (KS)     -  yes 
320 (KS) Chroma Spin -10 (dry) no no 
7190 (KS)     -  no 
7190 (KS) Chroma Spin -10 (dry) - no 
281 (KS)   -  no 
281 (KS) Chroma Spin -10 (dry) no yes 
NF22   no - 
NF22 Chroma Spin -10  no - 
NF22 Chroma Spin -100   no -  
NF77   no -  
NF77 Chroma Spin -10  no -  
NF77 Chroma Spin -400   no -  
NF84   no -  
NF84 Chroma Spin -10  no -  
NF84 Chroma Spin -400   no -  
NF95   no -  
NF95 Chroma Spin -10  no -  
NF95 Chroma Spin -100   no -  
NF100   no * 
NF100 Chroma Spin -10  no -  
NF100 Chroma Spin -100   no -  
NF109   no *  
NF109 Chroma Spin -10  no -  
NF109 Chroma Spin -100   no -  
- = not tested * = samples from the same block have amplified a 600 bp fragment 
KS = Katarina Stenshamn’s samples 
 
Purification with phenol/chloroform did not seem to improve the success of PCR. The 
samples that amplified a 600 bp fragment after phenol/chloroform purification 
(Control DNA, NF118 and EZ.xyl.wat.1) amplified it even without purification.  
The darker grey are results from the dry spin column (described in “3.2.3.2 
Purification of the gDNA”) and are therefore unreliable. This is also indicated by the 
result of 320 (KS), which amplified a 600 bp fragment before but not after the spin 
column. Despite of this, the result of 281 (KS) might indicate an advantage of spin 
column use, as this sample amplified a 600 bp fragment after spin column, but not 
before.  
The test with many spin columns would also be interesting to test in experiments of 
the 600 bp PCR. That might give more reliable results whether spin columns can 
improve PCR or not. While we have been unable to amplify an 850 bp fragment from 
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any of the paraffin-embedded samples it is currently impossible to see any change 
before and after the spin column.   
Using different dilutions of template DNA made no advantage and 50 ng in one 
reaction (of 20 µl) seemed to be an appropriate concentration. Altering MgCl2- and 
primer concentration resulted in one slightly better combination. The same samples 
were tested for all combinations and one sample was amplified in all combinations. 
When MgCl2 concentration was 2.5 mM and primer concentration was 0.4 µM one 
additional sample was amplified. This combination was then used in 850 bp PCR, but 
no sample was able to amplify the 850 bp fragment.  
All extracted samples were tested in a 600 bp PCR. All samples are, as mentioned 
earlier, listed in appendix 1, where the ones that amplified a 600 bp fragment are 
marked.  
The possible causes for the varying quality of the extracted gDNA will be 
discussed later and for this reason the samples with PCR result are sorted according to 
paraffin block age and listed in appendix 7.  
 
 4.3 Is desmin a DCM causing gene?  
The PCR used to amplify the microsatellite fragments were first tested with few 
samples and run in agarose gel electrophoresis (see figure 4). Other PCR programs 
and PCR mixes were tested, but none gave as nice bands on gel as the chosen 
protocol. This one was chosen to amplify microsatellite fragments from all samples 
(appendix 1). 
 
 
 
GEL 1:                
1kb 
ladder 
Microsatellite 1 
18 22 77 84 95 100 blank 
1kb 
ladder 
Microsatellite 2 
18 22 77 84 95 100 blank 
 
GEL 2: 
1kb 
ladder 
Microsatellite 3 
18 22 77 84 95 100 blank 
 
Positive controls  
for microsatellite  
1, 2 and 3 
 
 
 
Figure 4. Gel picture after test 
amplification in the chosen 
microsatellite PCR. 
 
After PCR, genotyping in MegaBACE and analysing raw data, different alleles and 
haplotypes were decided for the individuals, see appendix 8. Since only a few samples 
were able to amplify microsatellite 1, complete haplotypes could not be made for 
those individuals. Haplotypes of microsatellite 2 and 3, covering a region of 15.4 kb, 
which still include the desmin gene, were made and their association with DCM was 
calculated. No association was expected, and the haplotypes and alleles should then 
have an equal distribution between healthy and diseased. One haplotype that were 
found in one individual were not included in the calculations. The calculations for 
allele- and haplotype association are presented in table 6.  
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Table 6. Observed number of alleles/haplotypes compared to expected number if 
there is no association.  
       
Number  
expected   Contributions to 
 Observed number   under independence:  chi-square:  
                
Microsatellite 1                            
                  
Alleles 305 314 320    305 314 320   305 314 320   
Cases  1 1 5 7   2,00 0,50 4,50   0,50 0,50 0,06   
Controls  3 0 4 7   2,00 0,50 4,50   0,50 0,50 0,06   
  4 1 9 14             
             Chi-square: 2.11 df=2 
             
2-sided p-value: 
0.347999 
                                
Microsatellite 2                             
                  
Alleles 248 252     248 252    248 252    
Cases  2 21 23    1,18 21,82    0,57 0,03    
Controls 0 16 16    0,82 15,18    0,82 0,04    
  2 37 39              
             Chi-square: 1.47 df=1 
             
2-sided p-value: 
0.225877 
                                
Microsatellite 3                             
                  
Alleles 125 145 161 169   125 145 161 169  125 145 161 169 
Cases 18 2 9 3 32  18,37 1,78 9,48 2,37  0,00 0,03 0,02 0,17 
Controls  13 1 7 1 22  12,63 1,22 6,52 1,63  0,01 0,04 0,04 0,24 
  31 3 16 4 54            
             Chi-square: 0.56 df=3 
             
2-sided p-value: 
0.906204 
                                
Haplotype (microsatellite 2 & 3)                        
                  
  A B C D   A B C D  A B C D 
Cases 12 2 6 2 22  12,65 1,65 6,05 1,65  0,03 0,07 0,00 0,07 
Controls 11 1 5 1 18  10,35 1,35 4,95 1,35  0,04 0,09 0,00 0,09 
  23 3 11 3 40            
             Chi-square: 0.41 df=3 
             
2-sided p-value: 
0.939205 
 
                               
 
The hypothesis that there is no association can not be excluded, since the chi-square 
values are lower than table chi-square values. These results thereby support the 
hypothesis that there is no association between the desmin gene and DCM.  
 
5. Discussion 
 5.1 DNA-preparation 
Both tested paraffin purification methods (octane/methanol- and xylene- protocol) and 
the two extraction methods (salt preparation and E.Z.N.A. tissue DNA kit) resulted in 
gDNA from the paraffin-embedded samples tested. From all combinations of methods 
tested we were able to PCR-amplify fragments up to 600 bp. No obvious differences 
were noticed between the methods and further analyses were performed with samples 
purified with octane/methanol protocol and extracted with salt preparation. All 
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methods should perhaps be tested with more samples in order to get stronger 
arguments to use a particular combination. The E.Z.N.A. kit might give better result if 
more samples are tested. VWR bioMarke (2006) has presented supporting results for 
E.Z.N.A. tissue DNA kit, as they showed that 200 bp fragments could be amplified 
and DNA of higher molecular weight were present in all tested samples from paraffin-
embedded tissue. 
 Akalu and others (1999) reported that samples from paraffin-embedded tissue were 
able to amplify fragments up to 959 bp. In the reported study, gDNA was extracted 
with an extraction buffer (10 mM Tris–HCl, 1% Tween, 0.1 mg/ml proteinase K, 1 
mM EDTA, pH 8.0) and purified with QIAquick kit or phenol/chloroform (with 
ethanol precipitation). The amount of high molecular weight DNA after purification 
with QIAquick was significantly higher when the total gDNA was analysed on 
agarose gel. The gDNA was tested in PCR and some samples purified with QIAquick 
kit amplified fragments of 959 bp. These tests indicated clear improvements when kits 
were used, supporting the notion that the E.Z.N.A. kit in this study should have been 
tested with more samples. A report by Isola and others (1994) should also be 
considered. They reported that prolonged digestion with proteinase K improves the 
yield of gDNA. New tests with E.Z.N.A. samples should be digested with proteinase 
K over night, as in the salt preparation protocol, to ensure optimal yield.  
Other methods could also be tested. Tests of other paraffin purification and 
extraction methods were reported by Coombs and others (1999). A combination of 
digestion with proteinase K, paraffin purification with thermal cycler and gDNA 
extraction with Chelex-100 (media for DNA extraction) gave best results, as 61% of 
the analysed samples extracted PCR amplifiable DNA. They concluded that removal 
of paraffin and purification are main steps required to obtain good results. Techniques 
involving melting to remove paraffin were showed to be more effective compared to 
methods using organic solvents to dissolve the paraffin, and melting is also both safer 
and cheaper. This should be tested with the paraffin samples also in this study. Shi 
and others (2002) reported an extraction method involving heat-treatment and 
concluded that temperature and pH affect the outcome. High temperature, 120oC, and 
pH 6-12 showed satisfactory results, considering yield and amplification in PCR.  
Thus, it is apparent that multiple different methodologies are available for 
preparing gDNA from paraffin-embedded tissue. Different methods can be preferable 
in different tests and the optimal method in each given case has to be empirically 
determined.  
 
 5.2 gDNA from paraffin-embedded tissue 
The amount of extracted gDNA was not correlated with the amount of tissue, (see 
figure 3). This is probably due to which paraffin block that was used for extraction. 
Perhaps which part of the paraffin block also matter, since no correlation between 
samples from the same paraffin block (S.oct.1 & 2, S.xyl. 1 & 2, EZ.oct. 1 & 2 and 
EZ.xyl. 1 & 2) could be seen. The quality of extracted gDNA also differs between 
different paraffin blocks. 61 % (44 of 72) of the tested samples were able to amplify a 
fragment of around 100 bp or 200 bp (microsatellite 2 and 3), but only 18 % (13 of 
72) were able to amplify a fragment around 600 bp. No tested samples were able to 
amplify a fragment of around 850 bp. These results indicate that the gDNA is much 
degraded and this is a probable reason why additional purification steps do not 
improve the PCR.  
Degraded gDNA might influence the yield, of obtained gDNA from a certain 
amount of tissue, since it is possible that the precipitation efficiency differs between 
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long and short DNA fragments when gDNA is concentrated with precipitation. If this 
is true, samples with high yield would contain more gDNA of high molecular weight 
and should be able to PCR amplify a long fragment. In this study, the yield of the 
samples, able to amplify a 600 bp fragment, was compared to the yield of an equal 
amount of randomly picked samples that have not been able to amplify a 600 bp 
fragment. The samples used for this comparison are marked in appendix 1 and a 
figure comparing the values is presented in appendix 9. This comparison showed no 
difference in yield between the compared samples and both samples with high and 
low yield were able to amplify a 600 bp fragment. This might indicate that the 
samples that have not been able to amplify a 600 bp fragment not are as degraded as 
suspected and instead it could have been contaminations that disturbed the PCR. 
Another possible explanation is that the samples are slightly degraded and therefore 
give high yield, but are still too degraded to be able to amplify a long PCR fragment. 
To evaluate these possibilities, the gDNA samples should be separated on an agarose 
gel to estimate the distribution of gDNA of different molecular weight.  
The age of the paraffin block can be one possible cause of the poorer quality of the 
extracted gDNA. The list in appendix 7 was used to calculate proportions of how 
many samples from paraffin blocks of different age were are able to amplify PCR 
fragments of different sizes. The sample from the oldest paraffin block that could 
amplify a 600 bp fragment was embedded 1995, and this year was chosen as a border 
for the proportion calculation. 52 % (15/29) of the samples from paraffin blocks 
embedded from 1982 to 1994 were able to amplify PCR fragments. None could 
however amplify a fragment of 300 bp or longer. 72 % (31/43) of the samples from 
paraffin blocks embedded from 1995 to 2004 were able to amplify PCR fragments of 
100 bp to 600 bp. 35 % of all samples from 1995 to 2004 were able to amplify 
fragments of 300 bp to 600 bp. Many new samples were determined to have better 
quality than older samples, but the age of the paraffin block cannot be the only cause, 
as some samples from new paraffin blocks did not amplify any fragments and some 
old were able to amplify at least shorter fragments. Other causes than age alone must 
influence the quality and here follow some suggestions of possible explanations. The 
age and/or other condition of the dog, when deceased, might influence the quality of 
the tissue before fixation in paraffin. Another important aspect is the time from death, 
tissue removal and paraffin fixation. Perhaps could also the storage of the paraffin 
blocks influence the quality.  
 The samples with enough quality, that is the samples which could amplify a 600 bp 
fragment, can perhaps be used in whole genome association studies with the Illumina 
array system that allows shorter fragments to be analyzed compared to the Affymetrix 
array. Other samples that are more degraded can be used in other, microsatellite-
based, association studies. The gDNA might be good enough for other candidate gene 
approaches, and to obtain better results, shorter fragments including the 
microsatellites could be used. If the fragments are around 100 bp, more samples will 
probably give result and more complete haplotypes will give more significant 
association calculations.   
 No samples from paraffin-embedded tissue were able to amplify an 850 bp 
fragment, but the primers were functional for blood samples and can therefore be used 
in other studies..  
 
5.3 Candidate gene approach 
95 % (35/37) of the alleles of microsatellite 2 had the same length. This means that 
this is an uninformative genetic marker. This can be a reason why UCSC Genome 
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Browser did not recommend that repeat as a marker. The result based on this marker 
should therefore be considered with caution. A sequence containing GT-units repeated 
around 12 times, as microsatellite 2, would be expected to have more alleles and be 
polymorphic. The result in this study indicates loss of polymorphism in this region. 
One explaination to this can be that the repeated sequence is a part of a regulatory 
region and that the length has been selected for. The allele length of microsatellite 3 
had large differences and that is probably due to the length of the repeated unit, which 
is 5 bases (ATTTT). Only one deletion or insertion will decrease or increase the size 
notably.  
 Even the MegaBACE result could be discussed, as only some samples are tested 
twice. To confirm the obtained results the samples should be tested at least once more, 
in a new PCR and a new MegaBACE run. Perhaps blood samples can be added as 
controls.  
 Although the results are not completely conclusive they indicate no association 
between desmin and DCM in Newfoundland dogs. Desmin can still have associations 
with the disease, since the results do not exclude a regulatory mutation that influences 
the expression of desmin. It can also be a totally different gene which causes DCM 
and there are many candidates, which, as mentioned earlier, are known disease genes 
for DCM in humans.  
 When studying the pedigree of the sampled Newfoundland dogs, made in Progeny 
(ver. 6) by student Katarzyna Koltowska, there is a great variation in who get the 
disease or not. In one litter almost all get DCM, but in another almost none. This is 
not in total agreement with classical autosomal dominant inheritance. This originates 
the question if something else might influence the appearance of DCM. In a Ph.D. 
thesis by Polona Stabej (2005) referred to in a collected writing about molecular 
genetics of DCM (Stabej et al. 2006), the titin gene (TTN) has been genotyped in 
affected and unaffected dogs. The affected group displayed a variety of haplotypes, 
whereas the unaffected group mostly shared one haplotype. Stabej (2005) suggested, 
by these results, that the titin allele, which is common in the unaffected dogs, might 
confer protection against DCM (Stabej et al. 2006).  
 
 5.4 Conclusions and future studies 
The quality of gDNA prepared from paraffin-embedded tissue differs between blocks 
and gDNA from some blocks seems to be highly degraded. This study still shows that 
paraffin blocks can be used as source for gDNA in genetic studies. The paraffin 
purification and DNA extraction method used in this study was considered as a 
potential preparation method, as some samples were able to PCR-amplify a 600 bp 
fragment. Most samples were able to amplify samples around 100-200 bp, which 
make them useful for microsatellite analyses with fragments around that size.  
 To conclude the result of the candidate gene approach in this study, which 
indicated no association between desmin and DCM, at least one more informative 
marker should be involved. My suggestion is to use the known microsatellite, Des1, 
and design new primers for a smaller fragment that can be amplified in a sufficient 
number of samples to get complete haplotypes. All samples should also be tested at 
least twice, to confirm the result.  
 The samples that have not been able to amplify a 600 bp fragment should not be 
excluded from this project. Other purification steps or individual optimization of PCR 
might improve their success in PCR. Other extraction methods, as mentioned earlier, 
could also be tested. Samples, which can amplify a 600 bp fragment, can possibly be 
used in whole genome association mapping with the Illumina methodology or similar 
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approaches. The other samples, of poorer quality, can then be used for fine mapping if 
a suspected associated region is found.  
 
6. Acknowledgements  
First I would like to thank my supervisors Göran Andersson, Izabella Baranowska and 
Nicolette Salmon Hillbertz for all help and support, and Katarina Stenshamn, who has 
been a very good collaborator and has given me a lot of support. I would also like to 
thank Anna Tidholm, who has collected all paraffin blocks used in this study and has 
read the manuscript for this report. 
Further I want to thank the whole department of Animal Breeding and Genetics at 
SLU, in particular Ulla Gustafson for sequencing and advice.  
 
 7. Svensk sammanfattning 
Syftet med DCM-projektet är att hitta en genetisk koppling till hjärtsjukdomen 
dilaterad cardiomyopati (DCM) hos hundar av rasen Newfoundland. Den del som 
presenteras i denna rapport innefattar en utvärdering av DNA från paraffininbäddad 
vävnad och en kandidatgensundersökning där association mellan genen desmin och 
sjukdomen DCM utvärderas.  
DCM är en hjärtsjukdom som drabbar bland annat hundar och människor. 
Hjärtmuskeln blir förstorad eftersom hjärtat blir utvidgat och orkar inte pumpa 
ordentligt. Infektion kan vara en orsak till utveckling av DCM, men även andra 
orsaker finns. Sjukdomen kan i vissa fall ärvas och hos människa har man sett att det 
är en heterogen sjukdom med flera kända orsakande gener. Hos hund är sjukdomen 
homogen inom en ras och detta tillsammans med att stora regioner i hundens genom 
nedärvs tillsammans, vilket kallas ”linkage disequilibrium” (LD), gör att de passar bra 
för genetiska studier. Markörer i genomet jämförs mellan individer för att se vilka 
regioner som är lika i olika individer. 
Vävnad inbäddad i paraffin renades från paraffin och sedan extraherades DNA. För 
att utvärdera kvalitén på DNA gjordes olika tester i PCR utan eller med ytterligare 
reningssteg såsom fenol/kloroform-rening och spinkolonner. Alla tester resulterade i 
att kvalitén på DNA från paraffininbäddad vävnad inte är så bra och att det är stor 
skillnad mellan olika klossar. Dock fanns inget tydligt samband mellan vilka klossar 
som gav bra eller dåligt DNA, men en möjlig förklaring kan vara att det gått olika 
lång tid från det att vävnaden tagits från en patient tills det att den bäddats in i 
paraffin. Kvalitén var ändå tillräckligt bra för att amplifiera en del fragment med 
mikrosatelliter, som är repetitioner i genomet som används som genetiska markörer. 
Markörerna låg runt genen desmin och genom att jämföra markörerna i sjuka och 
friska hundar kunde ingen association mellan genen och sjukdomen hittas. Dock 
utgjordes haplotypen endast av två markörer varav en som inte var så informativ, 
d.v.s. det var samma allel i de flesta individerna. En ny studie med kortare fragment 
med mikrosatelliter eller andra DNA-prover skulle behöva göras.  
 
 22
8. References 
 8.1 Literature 
Akalu A., Reichardt J.K.V. (1999) A reliable PCR amplification method for 
microdissected tumor cells obtained from paraffin-embedded tissue. Genetic 
Analysis: Biomolecular Engineering 15: 229-233 
 
Alroy J., Rush J.E., Freeman L., Amarendhra Kumar M.S., Karuri A., Chase K., 
Sarkar S. (2000) Inherited infatile dilated cardiomyopathy in dogs: Genetic, clinical, 
biochemical, and morphologic findings. American Journal of Medicine Genetics 95, 
57-66  
 
Brown T.A. (2002) Chapter 2: “Genome anatomies” & Chapter 5: “Mapping 
genomes”. Genomes 2:nd ed., BIOS Scientific Publishers Ltd, Oxford 
 
Coombs N.J., Gough A.C., Primrose J.N. (1999) Optimisation of DNA and RNA 
extraction from archival formalin-fixed tissue. Nucleic Acids Research, vol. 27, no. 
16, e12 
 
Davies M.J. (1984) The cardiomyopathies: a review of terminology, pathology and 
pathogenesis. Histopathology 8:363-393 
 
Fatkin D., Graham R.M. (2002) Molecular Mechanisms of Inherited 
Cardiomyopathies. Physiol Rev. 82, 945-980 
 
Franz W-M., Müller O.J., Katus H.A. (2001) Cardiomyopathies: from genetics to the 
prospect of treatment. The Lancet vol. 358, 1627-1637 
 
Gibson G., Muse S.V. (2004) A primer of genome science. Second edition. Sinauer 
Associates, Inc Publishers. Massachusetts, USA.  
 
Goebel H.H. (1995) Desmin-related neuromuscular disorders. Muscle Nerve 
18:1306-1320 
 
Isola J., DeVries S., Chu L., Ghazvini S., Waldman F. (1994) Analysis of changes in 
DNA sequence copy number by comparative genomic hybridization in archival 
paraffin-embedded tumor samples. The American Journal of Pathology 145(6): 
1301-1308 
 
Karlsson E.K., Salmon Hillbertz N., et.al (2007) Two-stage association mapping in 
dogs identifies coat color locus. In preparation 
 
Kumar V., Contran R.S., Robbins S.L. (2003) Chapter 11: “The heart” Robbins 
Basic Pathology 7th edition, Saunders, Philadelphia 
 
Lazarides E. (1982) Intermediate filaments: A chemically heterogeneous, 
developmentally regulated class of proteins. Annual Reviews of Biochemistry 
51:219-50 
 
 23
Li D., Tapscoft T., Gonzalez O., Burch P.E., Quiñones M.A., Zoghbi W.A., Hill R., 
Bachinski L.L., Mann D.L., Roberts R. (1999) Desmin Mutation Responsible for 
Idiopathic Dilated Cardiomyopathy. Circulation 100:461-464 
 
Milner D.J., Weitzer G., Tran D., Bradley A., Capetanaki Y. (1996) Disruption of 
muscle architecture and myocardial degeneration in mice lacking desmin J. Cell 
Biol (Sep; 134 (5): 1255-70 
 
Milner D.J., Taffet G.E., Wang X., Pham T., Tamura T., Hartley C., Gerdes A.M., 
Capetanaki Y. (1999) The absence of desmin leads to cardiomyocyte hypertrophy 
and cardiac dilation with compromised systolic function. J Mol Cell Cardiol 31: 
2063-2076 
 
Page R.D.M., Holmes E.C. (1998) Chapter 3: “Genes: Organisation, Function and 
Evolution”. Molecular Evolution –A Phylogenetic Approach, Blackwell Science Ltd, 
UK 
 
Scheinin S., Capek P., Radovancevic B., Duncan J.M., McAllister H.A. Jr., Frazier 
O.H. (1992) The effect of prolonged left ventricular support on myocardial 
histopathology in patients with end-stage cardiomyopathy. ASAIO Journal 
38:M271-M274 
 
Schuelke M. (2000) An economic method for the fluorescent labeling of PCR 
fragments. Nature Biotechnology, vol. 18, Feb. 2000 
 
Shi S-R., Cote R.J., Wu L., Liu C., Datar R., Shi Y., Liu D., Lim H., Taylor C.R. 
(2002) DNA Extraction from Archival Formalin-fixed, Paraffin-embedded Tissue 
Sections Based on the Antigen Retrieval Principle: Heating Under the Influence of 
pH. The Journal of Histochemistry & Cytochemistry, vol 50(8): 1005-1011 
 
Stabej P., Imholz S., Versteeg S.A., Zijlstra C., Stokhof A.A., Domanjko-Petric A., 
Leegwater P.A.J., van Oost B.A. (2004) Characterization of the canine desmin 
(DES) gene and evaluation as a candidate gene for dilated cardiomyopathy in 
Dobermann Gene 340,241-249 
 
Stabej P. (2005) “Molecular genetics of dilated cardiomyopathy in Dobermann 
dog”. Ph.D. thesis, Utrecht University, The Netherlands (referred to in Stabej et al. 
2006)  
 
Stabej P., Meurs K.M., van Oost B.A. (2006) Molecular Genetics of Dilated 
Cardiomyopathy The Dog and Its Genome, Cold Spring Harbor Laboratory Press 0-
87969-742-3, 365-382 
 
Sutter N.B., Eberle M.A., Parker H.G., Pullar B.J., Kirkness E.F., Kruglyak L., 
Ostrander E.A. (2004) Extensive and breed-specific linkage disequilibrium in Canis 
familiaris. Genome Res. 14:2388-2396  
 
Tidholm A. and Jönsson (1996) Dilated Cardiomyopathy in the Newfoundland: A 
Study of 37 Cases (1983-1994). J Am Anim Hosp Assoc 32:465-470 
 
 24
Tidholm A., Jönsson L. (1997) A retrospective study of canine dilated 
cardiomyopathy (189 cases). J. Am. Anim. Hosp. Assoc. 33:544-550 
 
Tidholm A., Häggström J., Jönsson L. (1998) Prevalence of attenuated wavy fibers 
in the myocardium of dogs with dilated cardiomyopathy Journal of American 
Veterinary MedicalAssociation 212:1732-1734  
 
Tidholm A., Häggström J., Jönsson L. (2000) Detection of attenuated wavy fibers in 
the myocardium of Newfoundlands without clinical echocardiographic evidence of 
heart disease. Am J Vet Res, vol. 61, No. 3: 238-241 
 
Tidholm A. and Jönsson L. (2005) Histologic Characterization of Canine Dilated 
Cardiomyopathy. Vet. Pathol. 42:1-8 
 
VWR bioMarke, the Market Source for Life Science (2006) High quality Genomic 
DNA from Animal Tissues and Using E.Z.N.A.(R)Tissue DNA Kits. VWR 
International, issue 15 (fall) 
 
Zhenlin  Li,  Alain  Lilienhaum,  Gillian  Butler-Browneb  and  Denise  Paulin 
Human  desmin-coding  gene:  complete  nucleotide  sequence,  characterization  
and  regulation  of  expression  during  myogenesis  and  development 
(Recombinant  DNA;  intermediate  filaments;  intron;  exon;  hamster;  1 phage 
vectors;  promoter;  actin;  lariat;  Al141 repeat;  restriction  map;  vimentin)  Gene; 
78  (1989)  243-254    
 
8.2 Manuals 
BD CHROMA SPINTM Columns User Manual, no. PT1300-1, ver. PR49719, BD 
Biosciences -Clontech 
 
NanoDrop manual, ND-1000 Spectrophotometer V3.3 User’s Manual  
 
8.3 Internet references 
Ensembl: http://www.ensembl.org  
Ensembl Dog (CanFam1): release 40, Aug 2006 and release 41, Oct 2006 
Ensembl Pre Dog (CanFam2): v.38 
Ensembl Dog (CanFam2): release 42, Dec 2006 
 
NetPrimer: www.premierbiosoft.com/netprimer/index.html 
 
NCBI (Pubmed): http://www.ncbi.nlm.nih.gov  
 
Primer3: http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi 
 
TAG Copenhagen: http://www.tagc.com 
 
UCSC Genome Browser: http://genome.ucsc.edu 
Dog Assembly May 2005
 25
Appendix 1. Sample list, with tissue weight, NanoDrop result and result of 600 bp PCR. 
 
gram  ug DNA  Yield  ID from year Case/Control Sex 
paraffin sample in solution 
260/280 600 bp fragment 
in PCR Comparison*  
NF18 1994 control Female 0,0174 66,2 1,86 No   
NF19 1995 case Female       -  Missing block 
NF20 2004 control Male 0,0152 10,5 1,93 No   
NF21 2003 control   0,0203 34,1 1,96 No 1680  
NF22 1997 control Male - 71,1 1,89 No   
NF23 1997 case Male 0,0190 27,3 1,91 Yes 1437  
NF24 1998 case Female 0,0292 61,5 1,85 No   
NF25 1999 case Male 0,0219 23,7 2,01 Yes 1082  
NF26 1995 case Female 0,0130 33,9 1,86 No   
NF27 only blood case Female       -  No block 
NF66 1993 case Female 0,0310 22,7 1,89 No 732  
NF67 1999 control Female 0,0220 16,6 1,76 No   
NF72 only blood case         -  No block 
NF73 2000 case Female 0,0155 23,1 1,91 No   
NF74 1997 case Male 0,0142 20,9 1,94 Yes 1472  
NF75 1996 case Male 0,0270 27,8 1,91 No   
NF76 1996 case Female 0,0212 32,4 1,97 No 1528  
NF77 1997 case Female - 44,9 1,87 No   
NF78 1997 case   0,0224 30,7 1,92 No   
NF79 1996 case   0,0181 31 1,95 No   
NF80 1999 case   0,0260 31,1 1,97 Yes 1196  
NF81 1995 case   0,0197 91,3 2,01 No   
NF82 1997 case Female 0,0132 16,5 1,93 No   
NF83 1993 case   0,0110 26,4 1,88 No 2400  
NF84 1993 case Male - 56,9 1,82 No   
NF85 1993 case Female 0,0183 24,9 1,76 No   
NF86 1992 case   0,0226 37,8 1,92 No   
NF87 1999 case   0,0233 8,4 1,79 Yes 361  
NF88 1994 case   0,0219 21,1 1,89 No   
NF89 1996 case   0,0170 20,1 1,94 No   
NF90 1994 case   0,0302 10,4 1,84 No   
NF91 1991 case   0,0255 22,8 1,92 No   
NF92 1995 case   0,0189 22,6 1,91 No 1196  
NF93 1995 case   0,0236 16,9 1,94 No   
NF94 1995 case   0,0256 67 1,93 Yes 2617  
NF95 1992 case Female - 46,5 1,88 No   
NF96 1992 case Female 0,0140 21,6 1,96 No 1543  
NF97 1996 case Male 0,0216 24,2 1,88 No   
NF98 2001 case Male 0,0277 35,1 1,98 No   
NF99 2000 case   0,0195 14,9 1,72 No   
NF100 1998 case   - 31,1 1,92 Yes   
NF101 1989 case Female 0,0157 18,3 1,96 No   
NF102 1993 case   0,0189 39,4 1,92 No 2085  
NF103 2001 case Female 0,0158 25,3 1,94 No   
NF104 1996 case   0,0175 1,2 1,87 No   
NF105 1992 case Male 0,0150 19,5 1,90 No   
NF106 1991 case   0,0188 42,3 1,94 No   
NF107 1991 case Female 0,0250 65 1,99 No   
NF108 1999 case         -  Missing block 
NF109 1998 case Female - 229,4 1,91 Yes   
NF110 1998 case Female 0,0263 61 1,98 No   
NF111 1996 case   0,0142 12,6 1,91 No   
NF112 1996 case Female       -  Missing block 
NF113 1982 control   0,0220 27,6 1,87 No   
NF114 2001 control Female 0,0135 37,8 2,01 Yes 2800  
NF115 2001 control   0,0222 39,2 1,91 Yes 1766  
NF116 2001 control Female 0,0297 20,2 1,79 No   
NF117 1998 control   0,0274 19,3 1,85 No 704  
NF118 1998? control   0,0193 37,9 1,92 Yes 1964  
NF119 1994 control   0,0235 17,8 1,91 No   
NF120 1991 control   0,0260 42,4 1,87 No    
NF121 1989 control   0,0187 23,3 1,90 No   
NF122 1992 control   0,0247 23,1 1,76 No    
NF123 1993 control   0,0158 22,4 1,92 No 1418  
NF124 1993 control   0,0131 29,5 1,90 No   
NF125 1990 control   0,0201 20,2 1,95 No    
NF126 1991 control   0,0303 116,8 2,00 No   
NF127 1992 control   0,0186 29,9 1,97 No   
NF128 1995 control   0,0173 205,5 2,02 No  11879  
NF129 1992 control   0,0177 20,2 1,83 No   
NF130 1994 control   0,0256 49,4 1,90 No   
NF131 1992 control   0,0211 25,2 1,85 No    
NF132 1995 control   0,0222 51,2 1,93 No   
NF133 2002 control   0,0271 25,2 1,72 Yes 930  
NF134 2002 control   0,0218 18,1 1,82 No   
NF135 2000 control   0,0263 35,2 1,93 No 1338  
NF136 2000 control   0,0229 57,2 1,98 Yes 2498  
* see figure in appendix 9 
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Appendix 2. Paraffin extraction protocols
 
a) Paraffin Extraction  
via Octane/Methanol 
 
Reagents:  n-Octane 
100% Methanol 
 
Harmful reagents,  
use gloves and work in a hood.  
 
1. Add 1 ml of octane to the sample in 
a 1.5-2 ml microcentrifuge tube.  
  
2. Vortex vigorously for 10 sec (or 
until paraffin has detached from 
sample).  
 
3. Add 100 µl of 100% Methanol.  
 
4. Vortex vigorously. 
 
5. Centrifuge at 10.000 rpm for 2 min. 
(Octane forms upper layer, and 
methanol with tissue forms lower 
layer). 
 
6. Remove upper octane layer with 
fine tip transfer pipette.   
 
7. Spin for 1 min at 10.000 rpm.  
 
8. Remove residual octane layer.  
 
9. Remove methanol that pellets with 
the tissue (let stand to dry; 
CAUTION: Do not over dry as DNA 
may denature). 
 
10. Start DNA extraction protocol 
 
b) Xylene to extract paraffin  
(suggested in E.Z.N.A. tissue DNA 
kit) 
 
Xylene is harmful,  
use gloves and work in a hood.  
 
1. Put 30 mg tissue (about 2mm3) in a 
microcentrifuge tube. 
 
2. Extract the paraffin by adding 1 ml 
Xylene. Mix carefully with vortex.  
 
3. Centrifuge the tube at 10.000 x g 
(max. speed) for 10 minutes in room 
temperature. Throw away the 
supernatant (harmful waste) without 
touching the pellet.  
 
4. Wash the pellet with 1 ml absolute 
ethanol to remove traces of Xylene. 
Centrifuge at 10.000 x g for 5 min in 
room temperature. Throw away the 
ethanol without touching the pellet.  
 
5. Repeat the ethanol wash.  
 
6. Air-dry the pellet in 37oC for 15 
min.  
 
7. Start DNA extraction protocol or 
E.Z.N.A.-kit.
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Appendix 3. Standard (salt) protocol for DNA extraction 
 
 
DNA-preparation from muscle tissue  
 
1. Mix 
* about 50 mg tissue (homogenize) 
* 300 µl prep- buffer  
* 7,5 µl Proteinase K (stock 8mg/ml).  
 
2. Incubate in 50oC over night.  
 
3. Add 80 µl saturated NaCl, vortex, centrifuge at 9000 rpm for 10 min.  
Transfer the supernatant to a new tube.   
 
4. Repeat step 3 until the solution is clear (3-4 times). 
 
5. Add 800 µl 95% EtOH, turn the tube around, centrifuge at 13.000 rpm at least 45 
min. Throw away the supernatant and let the pellet dry (37oC). 
 
5b. (added in preparation of all samples) Wash the pellet with 500 µl 70% EtOH (turn 
around the tube). Centrifuge at 13.000 rpm for 10 min and throw away the 
supernatant. (This removes traces of NaCl, as the 30% water in the solution binds the 
salt.)  
 
6. Dissolve the pellet in 50 µl-100 µl 1 x TE.  
 
Prep-buffer (for one sample = 300µl)   
6 µl 5M NaCl      
3 µl 1M Tris-HCl     
15 µl 10% SDS       
276 µl water   
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Appendix 4. PCR protocols 
 
250bp- and 600bp- PCR (original version) 
(600bp version were modified in effort to improve amplification) 
Mix 
         1 well 
PCR Buffer II (x10)   2µl 
MgCl2 (25mM)    1.6 µl 
dNTP (20mM)    0.2 µl 
DMSO       1 µl 
Primer F (10 ng/µl)   0.6 µl 
Primer R (10 ng/µl)   0.6 µl 
AmpliTag Gold (5U/µl) 0.15 µl 
H2O        11.85 µl 
Transfer       18 µl/tube 
 
gDNA (25 ng/µl)    2 µl 
 
Program  
 
94oC  10 min 
94oC  30 sec 
69-54oC 30 sec   16 cycles 
72oC  45 sec 
 
94oC  30 sec 
54oC  30 sec   38 cycles 
72oC  45 sec 
 
72oC  5 min 
4oC   ∞
850bp- PCR (Des_ex456 and Des_ex7) (original version) (modified in some tests) 
Mix 
         1 well 
PCR Buffer II (x10)   2.5 µl 
MgCl2 (25mM)    2.0 µl 
dNTP (20mM)    0.25 µl 
Primer F (10 ng/µl)   0.5 µl 
Primer R (10 ng/µl)   0.5 µl 
AmpliTaq Gold (5U/µl) 0.20 µl 
H2O        17 µl 
Transfer       23 µl/tube 
 
gDNA (25 ng/µl)    2 µl 
Program 
 
94oC  5 min 
 
94oC  40 sec 
56oC  40 sec   40 cycles 
72oC  1 min 
 
72oC  5 min 
4oC   ∞ 
 
Microsatellite PCR (Des1, Des2 and Des3)   
 
Mix 
          1 well 
PCR Buffer II (x10)    1.25 µl 
MgCl2 (25mM)     1.25 µl 
dNTP (20mM)     0.125 µl 
Primer F (10 ng/µl) (M13 (-21)) 0.5 µl 
M13 (-21) Primer (20ng/µl) 0.19 µl 
Primer R (10 ng/µl)    0.375 µl 
AmpliTaq Gold (5U/µl)  0.10 µl 
H2O         8.71 µl 
Transfer       12.5 µl/tube 
 
gDNA (25 ng/µl)    2 µl 
Program 
 
94oC  5 min 
94oC  30 sec 
54oC   30 sec   10 cycles 
72oC  30 sec 
 
94oC  30 sec 
52oC  30 sec   30 cycles 
72oC  30 sec 
 
72oC  15 min 
4oC   ∞
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Appendix 5. Purification with phenol/chloroform (modified part of a DNA extraction 
protocol)
 
 
Phenol/chloroform protocol 
 
1. Add an equal volume (as DNA sample) water saturated phenol/chloroform to 
the sample (removes protein and fat). Vortex for about 1 minute. 
2. Centrifuge at 13.000 rpm in room temperature for 2 minutes. 
3. Transfer the upper phase (containing water and DNA) to a new eppendorf 
tube. Measure (or estimate) the volume.  
4. Add an equal volume chloroform+TE (remove phenol traces). Vortex and 
centrifuge as in step 2.  
5. Transfer the upper phase (water and DNA) to a new eppendorf tube. Measure 
(or estimate) the volume. 
6. Add 1/10 volume NaAC and 3 volumes ice cold absolute ethanol to precipitate 
the DNA.  
7. Turn the samples a couple of times and let stand in -20oC freezer for 2 hours.  
8. Centrifuge at 13.000 rpm for 10 minutes.  
9. Throw away the supernatant. 
10. Wash the pellet with 70 % ethanol (same volume as the absolute ethanol 
earlier). Centrifuge at 13.000 rpm for 10 minutes.  
11. Throw away the supernatant and let the pellet air-dry.  
12. Dissolve the pellet in 50 µl-100 µl 1 x TE.  
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Appendix 6. Measurements for yield calculations. E.Z.N.A. samples were eluted 
twice (in elution buffer and water). DNA amount in both elutions are used for total 
yield calculation.  
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Appendix 7. The samples with PCR result sorted according to age of paraffin block. 
 
Year ID 600 bp ~300 bp (Des1) ~250 bp (Des2) ~100 bp (Des3) 
1982 NF113     ok ok 
1989 NF101      
1989 NF121         
1990 NF125     ok   
1991 NF91   ok ok 
1991 NF106      
1991 NF107    ok 
1991 NF120    ok 
1991 NF126     ok   
1992 NF86   ok ok 
1992 NF95    ok 
1992 NF96    ok 
1992 NF105    ok 
1992 NF122      
1992 NF127   ok ok 
1992 NF129      
1992 NF131         
1993 NF66      
1993 NF83      
1993 NF84      
1993 NF85    ok 
1993 NF102      
1993 NF123      
1993 NF124         
1994 NF88    ok 
1994 NF90      
1994 NF18      
1994 NF119   ok ok 
1994 NF130     ok ok 
1995 NF26      
1995 NF81      
1995 NF92      
1995 NF93      
1995 NF94 ok  ok ok 
1995 NF128   ok ok 
1995 NF132     ok ok 
1996 NF75   ok ok 
1996 NF76  ok ok   
1996 NF79      
1996 NF89   ok ok 
1996 NF97    ok 
1996 NF104      
1996 NF111         
1997 NF23 ok  ok ok 
1997 NF74 ok  ok ok 
1997 NF77      
1997 NF78   ok ok 
1997 NF82   ok   
1997 NF22     ok ok 
1998? NF118 ok ok ok ok 
1998 NF24   ok ok 
1998 NF100 ok ok ok ok 
1998 NF109 ok ok ok   
1998 NF110 ok ok ok   
1998 NF117       ok 
1999 NF25 ok ok ok ok 
1999 NF80 ok  ok ok 
1999 NF87 ok  ok ok 
1999 NF67         
2000 NF73   ok ok 
2000 NF99   ok   
2000 NF135      
2000 NF136 ok ok ok ok 
2001 NF98   ok ok 
2001 NF103   ok ok 
2001 NF114 ok ok ok ok 
2001 NF115 ok ok ok ok 
2001 NF116     ok   
2002 NF133 ok  ok ok 
2002 NF134         
2003 NF21     ok ok 
2004 NF20         
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Appendix 8. Alleles and haplotypes for all tested individuals.  
Question mark means uncertain haplotype (one allele is missing) and allele size in 
bold text means that it is measured twice.  
 ID Des1 Des1 Des2 Des2 Des3 Des3   Des2 & 3-haplotype  Microsat. 2 & 3- 
Cases: NF23     252 252 125 125  A   haplotypes:  
 NF24     252 252 125 125  A       
 NF25 320 320 252 252 161 161  C   A: -.252.125 
 NF26                B: -.252.145 
 NF66                C: -.252.161 
 NF73     252 252 125 125  A   D: -.252.169 
 NF74     252 252 145 169  B D  E: -.248.125 
 NF75     252 252 145 169  B D    
 NF76 305 320 252 252          
 NF77                  
 NF78     252 252 125 125  A     
 NF79                  
 NF80     252 252 125 161  A C    
 NF81                  
 NF82     252 252          
 NF83                  
 NF84                  
 NF85         125 125       
 NF86     252 252 125 161  A C    
 NF87     252 252 125 161  A C    
 NF88         125 125       
 NF89     252 252 125 125  A     
 NF90                  
 NF91     252 252 125 161  A C    
 NF92                  
 NF93                  
 NF94     248 252 125 125  E A    
 NF95         125 125       
 NF96         161 169  C? D?    
 NF97         125 161       
 NF98     252 252 161 161  C     
 NF99     252 252          
 NF100 320 320 252 252 125 125  A     
 NF101                  
 NF102                  
 NF103     252 252 125 125  A     
 NF104                  
 NF105         125 125       
 NF106                  
 NF107         125 161       
 NF109 314 320 248 252          
 NF110 320 320 252 252          
 NF111                  
Controls: NF18                  
 NF20                  
 NF21     252 252 125 161  A C    
 NF22     252 252 145 161  B C    
 NF67                  
 NF113     252 252 125 125  A     
 NF114 305 320 252 252 125 125  A     
 NF115 305 320 252 252 125 125  A     
 NF116     252 252          
 NF117         125 161       
 NF118 320 320 252 252 161 169  C D    
 NF119     252 252 125 125  A     
 NF120         125 161       
 NF121                  
 NF122                  
 NF123                  
 NF124                  
 NF125     252 252          
 NF126     252 252          
 NF127     252 252 125 161  A C    
 NF128     252 252 125 161  A C    
 NF129                  
 NF130     252 252 125 125  A     
 NF131                  
 NF132     252 252 125 125  A     
 NF133     252 252 125 125  A     
 NF134                  
 NF135                  
 NF136 305 320 252 252 125 125   A     
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Appendix 9. Comparison of yield from samples that could and could not amplify 
a 600 bp fragment. 
 
 
 600bp not 
600bp 
Yield: 361 704 
(ng DNA /  930 732 
mg tissue) 1082 1196 
 1196 1338 
 1437 1418 
 1472 1528 
 1766 1543 
 1964 1680 
 2498 2085 
 2617 2400 
 2800 11879 
     
 18123 26503 
 
The highest value for "600 bp not amplified" is above the scale. 
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